Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Non-Current Deffered Revenue (2020 - 2022)

Lyell Immunopharma's Non-Current Deffered Revenue history spans 3 years, with the latest figure at $37.2 million for Q3 2022.

  • For Q3 2022, Non-Current Deffered Revenue fell 54.61% year-over-year to $37.2 million; the TTM value through Sep 2022 reached $37.2 million, down 54.61%, while the annual FY2021 figure was $79.7 million, 10.56% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2022 was $37.2 million at Lyell Immunopharma, up from $32.9 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $89.1 million in Q4 2020 and bottomed at $32.9 million in Q2 2022.
  • The 3-year median for Non-Current Deffered Revenue is $79.7 million (2021), against an average of $68.6 million.
  • The largest annual shift saw Non-Current Deffered Revenue decreased 10.56% in 2021 before it tumbled 59.79% in 2022.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $89.1 million in 2020, then dropped by 10.56% to $79.7 million in 2021, then tumbled by 53.35% to $37.2 million in 2022.
  • Per Business Quant, the three most recent readings for LYEL's Non-Current Deffered Revenue are $37.2 million (Q3 2022), $32.9 million (Q2 2022), and $77.9 million (Q1 2022).